title: [Cefixim: clinical pharmacology and role in therapy of urogenital infections].
abstract: Cefixim belongs to oral cephalosporins of the third generation and has the longest half-life period among all oral cephalosporins and, therefore can be taken once a day. Moreover, cefixim presents in high concentrations in the urine, kidneys and urinary tract. In vitro, this drug has high activity against basic pathogens of urogenital infection. A randomized clinical trial has found that cefixim has higher clinical and microbiological efficacy than ciprofloxacin in patients with acute uncomplicated cystitis.
authors.forename: V V
authors.initials: VV
authors.lastname: Rafal'skiĭ
authors.forename: E V
authors.initials: EV
authors.lastname: Divgan'
authors.forename: A V
authors.initials: AV
authors.lastname: Derevitskiĭ
mesh_terms: D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D020682:Cefixime / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D003556:Cystitis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D020682:Cefixime